The Story of Spinosad

What is spinosad and where does it come from? Learn how a beach vacation led an Eli Lilly scientist to discover this insect control molecule that kills fleas and prevents flea infestations in Trifexis® (spinosad + milbemycin oxime) and Comfortis® (spinosad).

Trifexis is approved for use in dogs and puppies 8 weeks of age or older and 5 pounds of body weight or greater.

Comfortis is a approved for use in cats 14 weeks of age or older and 2 pounds of body weight or greater, and dogs 14 weeks of age or older and 3.3 pounds of body weight or greater.

TRIFEXIS IMPORTANT SAFETY INFORMATION
The use of ivermectin at higher than FDA-approved doses at the same time as Trifexis can result in serious side effects. Treatment with fewer than three monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. Prior to administration of Trifexis, dogs should be tested for existing heartworm infection. Use with caution in dogs with pre-existing epilepsy. The most common adverse reactions reported are vomiting, lethargy, and itching. To ensure heartworm prevention, observe your dog for one hour after administration. If vomiting occurs within one hour, redose. Puppies less than 14 weeks of age may experience a higher rate of vomiting.

See the full product label for complete safety information at:
https://bit.ly/2XVVPva


COMFORTIS IMPORTANT SAFETY INFORMATION
For cats: Use with caution with concomitant extra-label use of ivermectin. The most common adverse reaction recorded in clinical trials was vomiting. Other adverse reactions were: lethargy, decreased appetite, weight loss and diarrhea. The safe use of Comfortis in breeding, pregnant or lactating cats has not been evaluated.

See the full product label for complete safety information at:
https://bit.ly/2m56iD5

For dogs: Following concomitant extra-label use of ivermectin with Comfortis, some dogs have experienced the following clinical signs: trembling/twitching, salivation/drooling, seizures, incoordination, excessive dilation of pupils, blindness and disorientation. Post-approval experience continues to support the safety of Comfortis when used concurrently with heartworm preventives according to label directions. The most common adverse reaction reported is vomiting. Other adverse reactions reported in decreasing order of frequency are depression/lethargy, decreased appetite, incoordination, diarrhea, itching, trembling, excessive salivation and seizures. Use with caution in breeding females and dogs with pre-existing epilepsy. The safe use of Comfortis in breeding males has not been evaluated.

See the full product label for complete safety information at:
https://bit.ly/2m56iD5

PM-US-19-0268